Sign In
Buy BCEL
$0.0900
+0 (+0%)
At Close: Sep 13, 2024
Best Penny Stocks to Watch This Week? 3 For Your Watch List
03:06pm, Sunday, 06'th Mar 2022
Are these penny stocks on your watch list for this week? The post Best Penny Stocks to Watch This Week?
Atreca, Inc. (BCEL) CEO John Orwin on Q4 2021 Results - Earnings Call Transcript
08:45pm, Friday, 04'th Mar 2022 Seeking Alpha
Atreca spikes as H.C. Wainwright welcomes updated data for cancer drug
04:00pm, Friday, 04'th Mar 2022 Seeking Alpha
The shares of micro-cap biotech, Atreca <> have added more than a third in morning hours on Friday to reach the highest level since Dec
Atreca, Inc. (BCEL) CEO John Orwin on Q4 2021 Results - Earnings Call Transcript
03:45pm, Friday, 04'th Mar 2022
Atreca, Inc. (BCEL) CEO John Orwin on Q4 2021 Results - Earnings Call Transcript
Atreca, Alignment top healthcare gainers; DBV Technologies, Ocugen lead losers'' pack
03:00pm, Friday, 04'th Mar 2022 Seeking Alpha
Atreca (BCEL) +20%. Alignment Healthcare (ALHC) +16%. DBV Technologies DBVT -22%. Ocugen OCGN -20%.
Atreca to Participate in Cowen 42nd Annual Healthcare Conference
01:30pm, Friday, 04'th Mar 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a uniqu
Atreca GAAP EPS of -$0.79 misses by $0.04 (NASDAQ:BCEL)
09:30pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Atreca press release (BCEL): Q4 GAAP EPS of -$0.79 misses by $0.04.As of December 31, 2021, cash and cash equivalents and investments totaled $148.1 million.
Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update
09:01pm, Thursday, 03'rd Mar 2022 GlobeNewswire Inc.
Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial
Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update
09:01pm, Thursday, 03'rd Mar 2022 GlobeNewswire
Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial
Atreca Q4 2021 Earnings Preview
10:35pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Atreca (NASDAQ:BCEL) is scheduled to announce Q4 earnings results on Wednesday, March 2nd, after market close.The consensus EPS Estimate is -$0.71 (-12.7% Y/Y) and the consensus…
Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022
09:30pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique
Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022
04:30pm, Thursday, 24'th Feb 2022
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d
Atreca, Inc. (BCEL) Upgraded to Buy: Here's What You Should Know
05:00pm, Tuesday, 08'th Feb 2022 Zacks Investment Research
Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atreca, Inc. (BCEL) Upgraded to Buy: Here's What You Should Know
01:04pm, Tuesday, 08'th Feb 2022
Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case
11:57am, Tuesday, 25'th Jan 2022
Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case
